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selection of particular groups of patients. However, the present
results can be seen as a basis for discussion about the very
restrictive practice regarding decisions on reinbursability of bari-
atric procedures. Further more, comprehensive quality assurance
is needed, including the implementation of competence centres
and the ﬁxing of minimum amounts for procedures. In this
context the long term assessment and evaluation of all patients
and their course of disease is necessary, aiming at the highest
possible effectiveness of medical treatment and still allowing for
economic limits.
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OBJECTIVES: The aim of this research was to evaluate the
cost-effectiveness of duloxetine as an additional treatment option
in the management of ﬁbromyalgia (FM), assessed from an NHS
Scotland health care system perspective. METHODS: We used a
3-year health state transition model to represent the sequential
drug management of patients with FM. Guidelines, evidence
reviews and clinical opinion were used to deﬁne a standard
treatment for Scotland based on tricyclic antidepressants (TCAs)
with switching to second-generation antidepressants (SSRIs or
SNRIs). The model considered two levels of pain response based
on an 11-point severity scale (0 = ‘no pain’ to 10 = ‘worst pain
possible’): 30% (response) and 50% (full response) change
from baseline score. Clinical efﬁcacy and discontinuation data
were taken from a systematic literature review and an adjusted
indirect meta-analysis based on placebo-controlled trials of FM
treatments. Utility data were linked to pain severity using trial-
based EQ-5D data collected from patients in the duloxetine
studies. Costing was based on 2006. Annual discounting was
applied equally at 3.5%. RESULTS: The ﬁrst-line use of dulox-
etine resulted in approximately 67 additional quality-adjusted
life years (QALYs) per 1000 patients, achieved at an additional
cost of £397,360. This corresponded to a cost per QALY of
£5950 compared to current standard treatment without dulox-
etine. These results were robust to both deterministic and proba-
bilistic sensitivity analyses, demonstrating a 70% probability of
the ICER falling below £15,000 per QALY. A step-wise analysis
reported a cost per QALY of £4847 for ﬁrst-line duloxetine
versus second-line treatment and £7360 versus third-line treat-
ment. CONCLUSIONS: There is currently a signiﬁcant unmet
need for patients with poorly controlled FM where pain is a
predominant symptom. These analyses show that the introduc-
tion of duloxetine into the standard treatment sequence for FM
could provide additional patient beneﬁts which should be con-
sidered cost-effective when compared to commonly adopted
thresholds.
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OBJECTIVES: Beneﬂur®, whose active principle is ﬂudarabine,
has an oral and an intravenous (i.v.) formulation. The objective
of the present study was to compare the efﬁciency of both
formulations by means of a cost-minimization analysis in the
treatment of B-cell chronic lymphocytic leukaemia (CLL) in
Spain. METHODS: Existence of previous clinical evidence on
the therapeutic equivalence between both ﬂudarabine formula-
tions justiﬁed a cost-minimization analysis to compare efﬁ-
ciency. The National Health System (NHS) perspective was
taken including only direct costs. Also indirect costs were con-
sidered allowing a societal viewpoint. Data on resources use
were obtained from published literature and through an expert
panel. Unit costs were obtained from Spanish costs databases.
Generic i.v. ﬂudarabine cost was used. The model was built in
Microsoft Excel and a sensitivity analysis by means of two dif-
ferent techniques (scenario analysis and Monte-Carlo Simula-
tion) was performed to ensure robustness of results. RESULTS:
Although acquisition costs for oral ﬂudarabine are higher than
for i.v. ﬂudarabine, higher administration costs for the i.v. for-
mulation due to hospital administration and adverse event
costs compensate them, resulting in net savings for the NHS of
€2152 and €1322 using the oral formulation (baseline sce-
nario), in monotherapy and in combined therapy respectively.
The range of savings obtained through the scenario analysis
was: €1024 €3280 for monotherapy and €617 €2027
for combined therapy. Indirect costs, i.e. lost productivity,
charge only i.v. ﬂudarabine, adding extra savings to the oral
formulation. Monte-Carlo results conﬁrmed model robustness.
CONCLUSIONS: Oral ﬂudarabine has equivalent efﬁcacy and
an improved safety proﬁle than intravenous ﬂudarabine
showing total lower costs both in monotherapy and in combi-
nation with cyclophosphamide, from the perspective of the
National Health System in Spain. Hence, oral ﬂudarabine
should be administered instead of intravenous ﬂudarabine
unless contra-indicated.
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OBJECTIVES: Chronic back and leg pain results in patients’
loss of function, reduced QoL and increased societal costs. The
objective was to assess health-related QoL (HRQoL) and health
resource utilization in failed back surgery syndrome patients. A
comparison of spinal cord stimulation plus non-surgical conven-
tional medical management (SCS group) versus non-surgical con-
ventional medical management alone (CMM group) was made
from the Spanish National Health System. METHODS: The
PROCESS study has been used as data source (Kumar 2007,
Manca 2008). 100 patients from 12 European, Canadian and
Australian hospitals (1 Spanish: Sant Pau Hospital, Barcelona),
were randomised to either the SCS or CMM group. Health care
resource consumption data, the implantable generator use in SCS
patients, hospital stay, and drug/non-drug pain-related treatment
were collected prospectively. Resource consumption costs were
obtained from local databases (eSalud and portalfarma data-
bases) using Spanish 2007 ﬁgures. HRQoL was assessed using
EuroQol-5D (EQ-5D) questionnaire and evaluated with Spanish
Time Trade Off tariffs. Both costs and outcomes were assessed
for each patient over the ﬁrst 6-months of the PROCESS trial.
RESULTS: The 6-month mean total health care cost in the SCS
group (€17,291; SD €4.243) was signiﬁcantly higher than in the
CMM group (€1,433; SD€2,088), with a mean difference of
€15,858 (95% CI: 14.548–17.173€). A reduction in drug costs
for SCS group was observed. However, the gain in HRQoL with
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